Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biocon Breaks Ground In Latin America Through Agreement In Brazil

Indian Firm Expands Partnership With Local Player Libbs

Executive Summary

Having together achieved success with biosimilar trastuzumab in Brazil, Biocon and local player Libbs Farmaceutica have reached an agreement to offer the Indian firm’s generic formulations in the market.

You may also be interested in...

Fresenius Kabi Breaks Into Brazilian Biosimilars Market

Fresenius Kabi has struck a deal with Brazilian organizations Fiocruz/Bio-Manguinhos and Bionovis to supply its Idacio biosimilar adalimumab rival to Humira for the next ten years.

Biocon Expands Into Middle East With Tabuk Partnership

Biocon is set to bolster its planned expansion into the MENA region through a partnership with Saudi firm Tabuk Pharmaceuticals, which will commercialize select Biocon generics in the Middle East.

Samsung Bioepis Launches Trastuzumab In Brazil

Samsung Bioepis has launched its Ontruzant rival to Herceptin in Brazil, claiming the first biosimilar trastuzumab to be supplied to the country’s public health system for early and metastatic HER2-overexpressing breast cancer.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts